SEC Form 4 · accession 0001567619-18-001754
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan W Ayers
Officer — Chairman, President & CEO · Director
Period of report
Aug 21, 2018
Accepted (ET)
Aug 23, 2018 · 6:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2018 | M | 10,000 | $43.71 | A | 1,073,469 | D | |
| Common StockF2 | Aug 21, 2018 | S | 7,000 | $243.2026 | D | 1,066,469 | D | |
| Common Stock | Aug 22, 2018 | M | 20,000 | $43.71 | A | 1,086,469 | D | |
| Common StockF3 | Aug 22, 2018 | S | 3,700 | $245.1191 | D | 1,082,769 | D | |
| Common StockF4 | Aug 22, 2018 | S | 12,300 | $245.894 | D | 1,070,469 | D | |
| Common Stock | Aug 23, 2018 | M | 10,000 | $43.71 | A | 1,080,469 | D | |
| Common StockF5 | Aug 23, 2018 | S | 7,000 | $247.3271 | D | 1,073,469 | D | |
| Common Stock | holding | — | — | — | 98,000 | I | by Ayers Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F7,F6 | $43.71 | Aug 21, 2018 | M | 10,000 | D | — | Feb 13, 2019 | Common Stock | 10,000 | 107,714 | D |
| Non-Qualified Stock Option (right-to-buy)F7,F6 | $43.71 | Aug 22, 2018 | M | 20,000 | D | — | Feb 13, 2019 | Common Stock | 20,000 | 87,714 | D |
| Non-Qualified Stock Option (right-to-buy)F7,F6 | $43.71 | Aug 23, 2018 | M | 10,000 | D | — | Feb 13, 2019 | Common Stock | 10,000 | 77,714 | D |
Explanation of responses
- F1Includes a total of 71 shares acquired under the registrant's Employee Stock Purchase Plan on March 30, 2018 and June 30, 2018.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $243.1748 to a high of $243.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $244.63 to a high of $245.57 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sales price of the shares sold ranging from a low of $245.69 to a high of $246.345 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average sales price of the shares sold ranging from a low of $247.32 to a high of $247.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6Grant of option to buy 58,857 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F7Not applicable.